ArticleFuture virology2008
Therapeutically targeting RNA viruses via lethal mutagenesis.
Article in Future virology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed.
- Genetic and phenotypic changes to Venezuelan equine encephalitis virus following treatment with β-D-N4-hydroxycytidine, an RNA mutagen.Scientific reports · 2024Article
- Treatment of highly virulent mammarenavirus infections-status quo and future directions.Expert opinion on drug discovery · 2024Review
- The Effect of Treatment-Associated Mutations on HIV Replication and Transmission Cycles.Viruses · 2022Review
- Marek's disease virus in vaccinated poultry flocks in Turkey: its first isolation with molecular characterization.Archives of virology · 2021Article
- Article
- Synergistic lethal mutagenesis of hepatitis C virus.Antimicrobial agents and chemotherapy · 2019Article
- Development of a fluorescence-based method for the rapid determination of Zika virus polymerase activity and the screening of antiviral drugs.Scientific reports · 2019Article
- Development and Validation of a Phenotypic High-Content Imaging Assay for Assessing the Antiviral Activity of Small-Molecule Inhibitors Targeting Zika Virus.Antimicrobial agents and chemotherapy · 2018Article
- Evidence for the Selective Basis of Transition-to-Transversion Substitution Bias in Two RNA Viruses.Molecular biology and evolution · 2017Article
- Molecular and Functional Bases of Selection against a Mutation Bias in an RNA Virus.Genome biology and evolution · 2017Article
- Triphosphate Reorientation of the Incoming Nucleotide as a Fidelity Checkpoint in Viral RNA-dependent RNA Polymerases.The Journal of biological chemistry · 2017Article
- Distinct Effects of T-705 (Favipiravir) and Ribavirin on Influenza Virus Replication and Viral RNA Synthesis.Antimicrobial agents and chemotherapy · 2016Article
- New strategies against drug resistance to herpes simplex virus.International journal of oral science · 2016Review
- Article
- Deep sequencing analysis of viral infection and evolution allows rapid and detailed characterization of viral mutant spectrum.Bioinformatics (Oxford, England) · 2015Article
- Effective lethal mutagenesis of influenza virus by three nucleoside analogs.Journal of virology · 2015Article
- Structural dynamics as a contributor to error-prone replication by an RNA-dependent RNA polymerase.The Journal of biological chemistry · 2014Article
- RNA virus population diversity, an optimum for maximal fitness and virulence.The Journal of biological chemistry · 2014Article
- Tautomerism provides a molecular explanation for the mutagenic properties of the anti-HIV nucleoside 5-aza-5,6-dihydro-2'-deoxycytidine.Proceedings of the National Academy of Sciences of the United States of America · 2014Article
- Genetic variation in vitro and in vivo of an attenuated Lassa vaccine candidate.Journal of virology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
RNA viruses exhibit increased mutation frequencies relative to other organisms. Recent work has attempted to exploit this unique feature by increasing the viral mutation frequency beyond an extinction threshold, an antiviral strategy known as lethal mutagenesis. A number of novel nucleoside analogs have been designed around this premise. Herein, we review the quasispecies nature of RNA viruses and survey the antiviral, biological and biochemical characteristics of mutagenic nucleoside analogs, including clinically-used ribavirin. Biological implications of modulating viral replication fidelity are discussed in the context of translating lethal mutagenesis into a clinically-useful antiviral strategy.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.